NCT04543916View on ClinicalTrials.gov

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2021

Primary Completion Date

May 30, 2028

Study Completion Date

June 30, 2028

Conditions
Relapsed Small Cell Lung CancerRefractory Small Cell Lung Carcinoma
Interventions
DRUG

Venetoclax 50 MG

Escalating doses to determine recommended phase 2 dose (RP2D)

DRUG

Venetoclax 100 MG

Escalating doses to determine recommended phase 2 dose (RP2D)

DRUG

Venetoclax 200 MG

Escalating doses to determine recommended phase 2 dose (RP2D)

DRUG

Venetoclax 400

Escalating doses to determine recommended phase 2 dose (RP2D)

DRUG

Venetoclax 600

Escalating doses to determine recommended phase 2 dose (RP2D)

DRUG

Irinotecan 60 mg/m2

Intravenously (IV), days 1, 8, and 15

DRUG

Venetoclax (RP2D)

orally, once per day

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Virginia Commonwealth University

OTHER